Source link : https://www.newshealth.biz/health-news/ifinatamab-deruxtecan-effective-in-es-sclc/
The antibody-drug conjugate ifinatamab deruxtecan (I-DXd) is effective in extensive-stage small cell lung cancer (ES-SCLC), with a higher dose of the drug almost doubling the response rate over a lower dose, suggests the phase 2 Ideate-lung01 study. The research, presented at the IASLC World Conference on Lung Cancer (WCLC) 2024 on September 8, also indicated […]
Author : News Health
Publish date : 2024-09-11 13:35:14
Copyright for syndicated content belongs to the linked Source.